Update on rifampin, rifabutin, and rifapentine drug interactions
- PMID: 23136913
- DOI: 10.1185/03007995.2012.747952
Update on rifampin, rifabutin, and rifapentine drug interactions
Abstract
Background: Rifampin is a potent inducer of both cytochrome P-450 oxidative enzymes and the P-glycoprotein transport system. Among numerous well documented, clinically significant interactions, examples include warfarin, oral contraceptives, itraconazole, digoxin, verapamil, simvastatin, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Rifapentine is also an inducer of drug metabolism.
Methods: A literature search of English language journals from 2008 to March 2012 was completed using several databases, including PubMed, EMBASE, and SCOPUS. Search terms included rifampin, rifabutin, rifapentine AND drug interactions.
Findings: Examples of clinically relevant interactions with rifampin demonstrated by recent reports include posaconazole, voriconazole, oxycodone, risperidone, mirodenafil, and ebastine.
Conclusions: To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin, rifabutin, or rifapentine are added to or discontinued from medication regimens, clinicians need to be aware of these interactions. Recent studies have indicated that other transporter systems play a role in these drug interactions. As reports of rifampin drug interactions continue to grow, this review is a reminder to clinicians to be vigilant.
Similar articles
-
Update on rifampin and rifabutin drug interactions.Am J Med Sci. 2008 Feb;335(2):126-36. doi: 10.1097/MAJ.0b013e31814a586a. Am J Med Sci. 2008. PMID: 18277121 Review.
-
Rifampin and rifabutin drug interactions: an update.Arch Intern Med. 2002 May 13;162(9):985-92. doi: 10.1001/archinte.162.9.985. Arch Intern Med. 2002. PMID: 11996607 Review.
-
Update on rifampin drug interactions, III.Arch Intern Med. 1997 Nov 24;157(21):2453-8. Arch Intern Med. 1997. PMID: 9385296 Review.
-
A regimen containing rifabutin for the treatment of tuberculosis in patients intolerant to rifampin.Clin Infect Dis. 2003 Jan 1;36(1):127-8. doi: 10.1086/345532. Clin Infect Dis. 2003. PMID: 12491218 No abstract available.
-
Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.MMWR Morb Mortal Wkly Rep. 2000 Mar 10;49(9):185-9. MMWR Morb Mortal Wkly Rep. 2000. PMID: 11795500
Cited by
-
Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes.Front Pharmacol. 2016 Apr 26;7:111. doi: 10.3389/fphar.2016.00111. eCollection 2016. Front Pharmacol. 2016. PMID: 27199754 Free PMC article.
-
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.Clin Infect Dis. 2016 Oct 1;63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10. Clin Infect Dis. 2016. PMID: 27516382 Free PMC article.
-
Adjunctive rifampin for the treatment of Staphylococcus aureus bacteremia with deep infections: A meta-analysis.PLoS One. 2020 Mar 19;15(3):e0230383. doi: 10.1371/journal.pone.0230383. eCollection 2020. PLoS One. 2020. PMID: 32191760 Free PMC article.
-
Polymorphism of CYP3A4*18 is associated with anti-tuberculosis drug-induced hepatotoxicity.Pharmacogenomics. 2024;25(5-6):241-247. doi: 10.1080/14622416.2024.2346069. Epub 2024 May 10. Pharmacogenomics. 2024. PMID: 38884784 Free PMC article.
-
Next-generation rifamycins for the treatment of mycobacterial infections.Proc Natl Acad Sci U S A. 2025 May 6;122(18):e2423842122. doi: 10.1073/pnas.2423842122. Epub 2025 May 1. Proc Natl Acad Sci U S A. 2025. PMID: 40310456 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials